title: As Spending Skyrockets for Direct-to-Consumer Prescription Drug Ads, So Does Pushback.
abstract: Arguments center on harm vs. benefit to patients and providers.
authors.forename: Roxanne
authors.initials: R
authors.lastname: Nelson
mesh_terms: D000329:Advertising / Q000191:economics*; D055553:Prescription Drugs / Q000191:economics*; D014481:United States
chemical_list: D055553:Prescription Drugs